High proliferative activity may predict early metastasis of thin melanomas

被引:32
作者
Frahm, SO
Schubert, C
Parwaresch, R
Rudolph, P
机构
[1] Univ Kiel, Dept Pathol, D-24105 Kiel, Germany
[2] Univ Kiel, Dept Hematopathol, D-24105 Kiel, Germany
[3] Inst Dermatopathol, Buchholz, Germany
关键词
thin melanoma; proliferation; Ki-S5; metastasis;
D O I
10.1053/hupa.2001.29658
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Metastasis of thin melanomas is uncommon and unpredictable. We prospectively investigated the clinical course of 167 thin melanomas (< 1 mm thickness) over a median observation period of 4 years (18 to 87 months). In addition to Breslow thickness, Clark level, and growth phase characteristics, we assessed cellular proliferation by counting mitoses and inummohistochemically using the monoclonal antibody Ki-S5 (Ki-67). Mitotic and Ki-S5 indices were correlated to tumor thickness, Clarks level, and radial/vertical growth phase (RGP/VGP). However, 5 tumors had proliferation indices above 25% (outside the range of a theoretical normal distribution). Four of these tumors metastasized, and none of the melanomas with lower proliferative activity progressed during the observation period. The metastatic behavior was independent of tumor thickness and Clark level and did not unconditionally coincide with VGP or high mitotic counts. It is concluded that the immunohistochemical proliferation index may be a powerful predictor of early systemic progression in thin melanomas, which may be helpful in making therapeutic decisions. Further investigations are needed to determine die value of proliferation measurements for the long-term prognosis of thin melanomas. Copyright (C) 2001 by W.B. Saunders Company.
引用
收藏
页码:1376 / 1381
页数:6
相关论文
共 69 条
[1]  
Bani MR, 1996, CANCER RES, V56, P3075
[2]   WET AUTOCLAVE TECHNIQUE - THE SIMPLER METHOD OF ANTIGEN RETRIEVAL [J].
BANKFALVI, A ;
RIEHEMANN, K ;
OFNER, D ;
CHECCI, R ;
MORGAN, JM ;
PIFFKO, J ;
BOCKER, W ;
JASANI, B ;
SCHMID, KW .
PATHOLOGE, 1994, 15 (06) :345-349
[3]  
BarEli M, 1997, J CELL PHYSIOL, V173, P275, DOI 10.1002/(SICI)1097-4652(199711)173:2<275::AID-JCP35>3.0.CO
[4]  
2-C
[5]  
Barnard J.L., 1991, Records of the Australian Museum, P1, DOI 10.3853/j.0812-7387.13.1991.91
[6]  
Barnhill RL, 1997, CANCER, V79, P423
[7]   THIN MALIGNANT MELANOMAS (LESS-THAN-1.5 MM) WITH METASTASIS - A HISTOLOGICAL STUDY AND SURVIVAL ANALYSIS [J].
BLESSING, K ;
MCLAREN, KM ;
MCLEAN, A ;
DAVIDSON, P .
HISTOPATHOLOGY, 1990, 17 (05) :389-395
[8]   THICK MALIGNANT MELANOMAS (GREATER-THAN-3 MM BRESLOW) WITH GOOD CLINICAL OUTCOME - A HISTOLOGICAL STUDY AND SURVIVAL ANALYSIS [J].
BLESSING, K ;
MCCLAREN, KM ;
MCLEAN, A ;
DAVIDSON, P .
HISTOPATHOLOGY, 1991, 18 (02) :143-148
[9]  
Blessing K, 1999, HISTOPATHOLOGY, V34, P189
[10]   MIB-1 immunoreactivity correlates with metastatic dissemination in primary thick cutaneous melanoma [J].
Boni, R ;
Doguoglu, A ;
Burg, G ;
Muller, B ;
Dummer, R .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1996, 35 (03) :416-418